share_log

四环医药(00460.HK):轩竹生物与SignalChem合作开发药品XZB-0004获批进行晚期实体瘤、血液系统恶性肿瘤临床试验

Fourth Ring Medicine (00460.HK): XZB-0004, a drug jointly developed by Xuan Zhu Bio and SignalChem, is approved for clinical trials of advanced solid tumors and hematological malignant tumors

Gelonghui Finance ·  May 26, 2022 12:30

On May 26th, Gelonghui, Sihuan Medicine (00460.HK) announced that Xuanxuan Bamboo Biology, a subsidiary of the Group,The declared XZB-0004 (SLC-391) capsule, a highly active and highly selective AXL targeting inhibitor, has successfully obtained the implied permission of the State Drug Administration to carry out clinical trials for the treatment of advanced solid tumors and hematological malignant tumors. Xuan bamboo organismIn September 2021 with SignalChem Life sciences Corporation ("SignalChemCooperation has been reached to introduce exclusive development and commercialization rights for the drug in Greater China.

SLC-391 is an effective, highly selective and oral targeted inhibitor of small molecular AXL, and the current preclinical data suggest that it is "Best-in-Class"."potential to become"First-in-Class". The product is currently in a phase I clinical study in Canada. Earlier, SignalChem has reached a cooperation with Merck & Co Inc (MSD) to jointly evaluate SLC391 and Keytruda.®(pembrolizumab) is used in combination with drugs.Efficacy in the treatment of advanced non-small cell lung cancer (Non-small cell lung cancer, NSCLC). Data from preclinical studies show that SLC-391 compounds are present in different animal models including NSCLC, colon cancer, chronic myeloid leukemia (chronic myeloid leukemia,CML) and acute myeloid leukemia (acute myeloid leukemia).AMLThere is a good curative effect in the model. Treatment synergies with other approved therapies have been shown in different models. Preclinical and phase I clinical results show that SLC-391 not only has a single drug effect in multiple solid tumors and hematoma trials, but also can potentially be combined with a variety of drugs under development in Xuan bamboo biological pipeline to treat some refractory tumors.

Lung cancer is the second highest incidence type of cancer in China, of which NSCLC is the most common type of lung cancer, accounting for 84% of all confirmed lung cancer cases. The 5-year overall survival rate is very low, only 24%, including 61% of local non-small cell lung cancer to 6% of metastatic non-small cell lung cancer. AML is a high clinical recurrence rate of refractory myeloid hematopoietic stem ╱ progenitor cell malignant disease, is one of the most common but also the most fatal types of leukemia. According to statistics from the American Cancer Society (American Cancer Society, ACS), there were about 6. 5% in the United States in 2020.530000 new cases of leukemia and 2.310000 cases of leukemia died, of which new cases of AML accounted for about 1..9.94 million cases, and about 1..1.18 million people died of AML. In China, with targeted drugs such as BCL2 inhibitor WirantoApproval for listing in 2020 brings new treatment options for patients who cannot tolerate strong induction chemotherapy. SLC-391 has a huge market potential in the clinical combination of drugs in the treatment of these diseases.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment